

BLAU FARMACÊUTICA S.A.

Publicly Held Corporation
CNPJ/MF 58.430.828/0001-60
NIRE 35.300.416.406
CVM Code 2462-7

NOTICE TO THE MARKET**Blau will join four B3 indexes - SMLL, ICON, IGCT and IBrA**

BLAU FARMACÊUTICA S.A. ("Blau" or "Company"), one of the main Brazilian pharmaceutical companies in Latin America focused on the production of highly complex medicines for the institutional segment, announces that, between January 3rd, 2022 and April 29th, 2022, the shares of our issue will be integrated in the Small Cap Index ("SMLL"), Consumption Index ("ICON"), Corporate Governance Trade Index ("IGCT") and Brazil Broad-Based Index ("IBrA"), prepared and published by B3 S.A. – Brasil, Bolsa, Balcão ("B3").

The Company will be listed in a total of 4 indexes on B3, which contributes to a potential value creation for its shareholders, expansion of the institutional investor base and the liquidity of BLAU3 shares.

Cotia, December 30th, 2021.

Melissa Angelini
Investors Relation Officer

About Blau Farmacêutica:

Blau is a leading pharmaceutical industry in the institutional segment and a pioneer in biotechnology, with an owned brands portfolio of highly complex drugs focused on relevant segments in the industry, such as immunology, hematology, oncology, specialties, antibiotics in various classes, among others.

Blau has a continental footprint, present in 6 countries in Latin America and the United States and has a modern pharmaceutical industrial complex, composed of four industrial plants, with cutting-edge technology, dedicated to the production of biological, biotechnological, oncological, antibiotic, anesthetic drugs injectables and biotechnological ingredients.